MedPath

Investigating the effect of Attentalin in children with hyperactivity attention deficit disorder

Phase 3
Recruiting
Conditions
Hyperactivity attention deficit disorder.
Attention-deficit hyperactivity disorder, predominantly inattentive type
F90.0
Registration Number
IRCT20240520061849N1
Lead Sponsor
Arak University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
108
Inclusion Criteria

Patients with attention deficit hyperactivity disorder
Informed consent of the patient's parents or legal guardian to participate in the study
Children 6 to 9 years old

Exclusion Criteria

History of drug side effects after taking Attentalin

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath